Acrivon Therapeutics, Inc. Logo

Acrivon Therapeutics, Inc.

Develops precision cancer therapies by matching patients to drugs using its proteomics platform.

ACRV | NDAQ

Overview

Corporate Details

ISIN(s):
US0048901096
LEI:
Country:
United States of America
Address:
480 ARSENAL WAY, SUITE 100, 2472 WATERTOWN
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted cancer therapies. The AP3 platform utilizes phosphoproteomics to analyze the biologic drivers of a patient's cancer, enabling the creation of predictive 'OncoSignature' tests. This method is designed to match drug candidates with patients whose tumors are most likely to respond, aiming to improve therapeutic outcomes beyond what is achievable with genomics. Acrivon's pipeline is led by ACR-368, a selective kinase inhibitor in Phase 2 clinical trials for various solid tumors. The company also advances its internally developed programs and seeks strategic partnerships to apply its AP3 platform to co-develop predictive tests for external drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Acrivon Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Acrivon Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Acrivon Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Larimar Therapeutics, Inc. Logo
Clinical-stage biotech developing protein therapies for rare diseases like Friedreich's ataxia.
United States of America LRMR
LEAP THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing targeted immuno-oncology antibody therapies for cancer.
United States of America LPTX
Lidds AB Logo
Develops oncology drugs using a technology for local, controlled, and sustained drug release.
Sweden LIDDS
LigaChem Biosciences Inc. Logo
Advancing a next-gen ADC platform to develop innovative medicines for unmet needs.
South Korea 141080
LIGAND PHARMACEUTICALS INC Logo
Acquires drug royalties and licenses proprietary technologies to biopharmaceutical partners.
United States of America LGND
LIKE,Inc. Logo
Provides comprehensive lifestyle support in childcare, human resources, and nursing care services.
Japan 2462
Linical Co., Ltd. Logo
Global CRO providing full-service drug development support for biopharma companies.
Japan 2183
Linkers Corporation Logo
A technology matchmaking platform for manufacturers to solve challenges and foster innovation.
Japan 5131
Lipidor AB Logo
Develops topical skin treatments by reformulating drugs with a lipid-based delivery platform.
Sweden LIPI
MAIA Biotechnology, Inc. Logo
Developing telomere-targeting immuno-oncology therapies for difficult-to-treat cancers.
United States of America MAIA

Talk to a Data Expert

Have a question? We'll get back to you promptly.